Open AccessWill Imatinib Compromise Reproductive Capacity?
Author(s) -
Zamah Alberuni M.,
Mauro Michael J.,
Druker Brian J.,
Oktay Kutluk,
Egorin Merrill J.,
Cedars Marcelle I.,
Rosen Mitchell P.
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0137
Subject(s) - medicine , imatinib , imatinib mesylate , oncology , fertility preservation , fertility , population , environmental health , myeloid leukemia
Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia‐positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic chemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.